Sector News

Stada CEO ‘happy’ to take 40% pension cut. Sound foreign, U.S. pharma chiefs?

November 14, 2014
Life sciences
Here’s something you don’t see in the U.S.: The chief exec of Germany’s largest independent pharma has agreed to a pension cut worth about 40%–a change he says he was “happy” to consent to.
 
Stada CEO Hartmut Retzlaff’s retirement package will get a €16 slim-down to about €24 million ($29.9 million), Reuters reports. Retzlaff waived the money before taxes as part of a transfer of the package from Stada to an external pension fund, which had been “planned for a long time,” the company’s CFO said on a conference call Thursday.
 
The package for the 21-year helmsman is a far cry from the kind of money long-tenured pharma CEOs can take home in the States. For comparison, former Johnson & Johnson chief Bill Weldon took home a $143 million package when he retired in 2012 after a 40-year stint at the New Jersey drugmaker, with 10 of those years spent in the CEO’s chair.
 
But in Europe, citizens have been known to raise fury over large retirement packages. Just ask former Novartis skipper Daniel Vasella, who saw his 72-million-franc ($74.4 million) goodbye present whittled down to $5.2 million after protests from pay watchdogs. (Swiss voters later passed a referendum giving shareholders the right to reject pay packages for top managers).
 
So while Retzlaff said on the call that he “was happy to” agree to the change in plan–which he didn’t have to do, he noted–he also made the case for the sum he’s still due after retirement.
 
“We managed under my leadership to turn this company, which at the time was already almost a hundred years old, from little better than a rabbit hutch into a reputable MDAX company,” he said, as quoted by Reuters.
 
By Carly Helfand
 

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach